Biomarin Pharmaceutical Inc (BMRN) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Total Cash From Operating Activities Chart for Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc (BMRN) operating cash flow for FY2025 was USD 828.0M, a 44.5% change from FY2024. Biomarin Pharmaceutical Inc's operating cash flow moved from USD -8.1M in 1998 to USD 828.0M in 2025 over 27 years. Operating cash flow compound annual growth rate: 5-year CAGR of 57.5%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $10.88B
- Implied Share Price
- $56.22
- Enterprise Value
- $15.37B
- Revenue (TTM)
- $3.41B
- EBITDA
- $645.32M
- Profit Margin
- 2.14%
- Trailing P/E
- 151.95
- Forward P/E
- 9.40
- Price/Book (MRQ)
- 1.90
- Price/Sales (TTM)
- 3.19
- EV/EBITDA
- 39.85
- EV/Revenue
- 4.51
- Dividend Yield
- —
- Book Value
- $32.66
- Free Cash Flow (FY2025)
- $724.96M
- Free Cash Flow Yield
- 6.66%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.